Carol Gallagher

Dr. Gallagher is a veteran board director and also currently serves as a venture partner at New Enterprise Associates (NEA), a global venture capital firm. Over the last ten years she has served as a director at multiple public and private companies. In these roles, she has been involved in multiple IPOs and several successful M&A transactions. She currently serves as a director at Atara Biotherapeutics and Frazier Lifesciences Acquisition Corp and until recently, Turning Point Therapeutics which was acquired by Bristol Myers Squibb in August, 2022. From 1989 through 2011, she served in roles of increasing responsibility within Eli Lilly, Amgen, Agouron Pharmaceuticals, Pfizer, Idec Pharmaceuticals, CancerVax, and Anadys Pharmaceuticals. With over thirty years of biopharma industry experience, she brings commercial, business development, and drug development skills and expertise. From 2008-2011, she was CEO of Calistoga Pharmaceuticals where she led its successful acquisition by Gilead Sciences in 2011. She attended Vanderbilt University and earned both a bachelor of science and a doctor of pharmacy degree from the University of Kentucky College of Pharmacy.